VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Wednesday, January 14, 2026

Stock Comparison

AbbVie Inc. vs GSK plc

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

AbbVie Inc.

ABBV · New York Stock Exchange

Market cap (USD)$389B
Gross margin (TTM)
Operating margin (TTM)
Net margin (TTM)
SectorHealthcare
Industry
CountryUS
Data as of2026-01-11
Moat score
65/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into AbbVie Inc.'s moat claims, evidence, and risks.

View ABBV analysis

GSK plc

GSK · London Stock Exchange

Market cap (USD)$75.9B
Gross margin (TTM)72.4%
Operating margin (TTM)23.5%
Net margin (TTM)17.1%
SectorHealthcare
IndustryDrug Manufacturers - General
CountryGB
Data as of2025-12-28
Moat score
62/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into GSK plc's moat claims, evidence, and risks.

View GSK analysis

Comparison highlights

  • Moat score gap: AbbVie Inc. leads (65 / 100 vs 62 / 100 for GSK plc).
  • Segment focus: AbbVie Inc. has 6 segments (47.4% in Immunology); GSK plc has 3 segments (37.6% in Specialty Medicines).
  • Primary market structure: Oligopoly vs Oligopoly. Pricing power: Moderate vs Strong.
  • Moat breadth: AbbVie Inc. has 3 moat types across 2 domains; GSK plc has 4 across 3.

Primary market context

AbbVie Inc.

Immunology

Market

Immunology therapies for autoimmune diseases (biologics and small molecules; e.g., IL-23, JAK, TNF)

Geography

Global

Customer

Prescribing specialists (rheumatology, dermatology, gastroenterology), payers (PBMs/insurers), patients

Role

Innovator biopharma (R&D, clinical development, regulated manufacturing, commercialization)

Revenue share

47.4%

GSK plc

Specialty Medicines

Market

Branded specialty pharmaceuticals (HIV, oncology, immunology/respiratory)

Geography

Global

Customer

Hospitals, specialist physicians, payers

Role

Innovator & branded manufacturer

Revenue share

37.6%

Side-by-side metrics

AbbVie Inc.
GSK plc
Ticker / Exchange
ABBV - New York Stock Exchange
GSK - London Stock Exchange
Market cap (USD)
$389B
$75.9B
Gross margin (TTM)
n/a
72.4%
Operating margin (TTM)
n/a
23.5%
Net margin (TTM)
n/a
17.1%
Sector
Healthcare
Healthcare
Industry
n/a
Drug Manufacturers - General
HQ country
US
GB
Primary segment
Immunology
Specialty Medicines
Market structure
Oligopoly
Oligopoly
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
Moderate
Strong
Moat score
65 / 100
62 / 100
Moat domains
Legal, Demand
Supply, Legal, Demand
Last update
2026-01-11
2025-12-28

Moat coverage

Shared moat types

IP Choke Point

AbbVie Inc. strengths

Regulated Standards PipeBrand Trust

GSK plc strengths

Capex Knowhow ScaleCompliance AdvantageSwitching Costs General

Segment mix

AbbVie Inc. segments

Full profile >

Immunology

Oligopoly

47.4%

Oncology

Competitive

11.6%

Neuroscience

Competitive

16%

Aesthetics

Oligopoly

9.2%

Eye Care

Competitive

4%

Other Key Products

Competitive

11.9%

GSK plc segments

Full profile >

Vaccines

Oligopoly

29.1%

Specialty Medicines

Oligopoly

37.6%

General Medicines

Competitive

33.2%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.